AGP Executive Report
Last update: 2 hours agoClinical Breakthrough: The LiBBY trial at the Alzheimer’s Association International Conference reported positive results for a THC/CBD oral rapid-acting formulation (2 mg THC + 100 mg CBD) to reduce agitation in hospice-eligible late-stage dementia patients. Regulatory Watch: Minnesota’s Office of Cannabis Management is holding a community Q&A in Mankato as adult-use sales expand. Policy & Access Clash: Virginia’s new recovery residence certification rules are still forcing legal medical cannabis patients to choose between treatment and housing. Industry & Politics: Major cannabis firms donated millions to Trump-aligned super PACs, underscoring a fast-shifting lobbying landscape across marijuana, hemp, and alcohol. Public Safety/Compliance: DEA rescheduling-related inspections are ramping up, with guidance emerging on how federal oversight may layer on top of state rules. Hemp Policy: A bipartisan “Lawful Hemp Protection Act” would create a national regulatory framework and revisit the THC limits that could squeeze most hemp products. Youth Use Concern: A large U.S. study finds substance experimentation rises sharply by mid-adolescence, with girls overtaking boys around age 13. Travel Warning: Thailand is tightening penalties for cannabis possession, with up to 10 years in prison reported under new customs rules.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[THC/CBD Combination Cuts Agitation in Hospice-Eligible Dementia: LiBBY Trial]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/26978646-929361567-92b25d8649127e50e9de5b21b5adcaa250a0ceb2-1200x628-100x52.png)
![<![CDATA[THC/CBD Combination Cuts Agitation in Hospice-Eligible Dementia: LiBBY Trial]]>](/images/news-fallback.svg)
